Ankasa Regenerative Therapeutics

Ankasa is developing ART352-L as a novel regenerative medicine. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need. Ankasa’s lead indication is augmentation of autograft used in spinal fusion for treatment of degenerative changes in intervertebral discs, a highly prevalent chronic, debilitating condition that can severely impact day-to-day functioning. Our preclinical data suggest that treatment of a patient’s autograft with ART352-L will generate significantly more bone without unwanted bone overgrowth, thus reducing the rate of revision surgeries and their attendant complications. This is a direct benefit to the target patient population as well as a direct savings to the healthcare system.